Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV ‐2 orCOVID ‐19)
Autor: | Samuel Seidu, Kamlesh Khunti, Sachin Khunti, Nitisha Khunti |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Endocrinology Diabetes and Metabolism Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 030209 endocrinology & metabolism 030204 cardiovascular system & hematology World health 03 medical and health sciences 0302 clinical medicine Endocrinology Metabolic Diseases Pandemic Internal Medicine Humans Hypoglycemic Agents Medicine Intensive care medicine Glucocorticoids Pandemics Aged Clinical Trials as Topic SARS-CoV-2 business.industry Brief Report Uncertainty COVID-19 Chloroquine Middle Aged Increased risk Cardiovascular Diseases Female Brief Reports type 2 diabetes business Delivery of Health Care Emergency healthcare Hydroxychloroquine |
Zdroj: | Diabetes, Obesity and Metabolism Diabetes, Obesity & Metabolism |
ISSN: | 1463-1326 1462-8902 |
DOI: | 10.1111/dom.14062 |
Popis: | Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 or COVID‐19) has been declared a pandemic by the World Health Organization and sent all countries scrambling to review emergency healthcare provisions. There is global evidence of each nation struggling to effectively manage the number of people being diagnosed with the virus. These are testing times which have not been experienced in recent generations and there are a number of insecurities regarding the management of people with COVID‐19 and cardiometabolic diseases. This review highlights the current concerns related to COVID‐19 and provides advice in terms of the therapeutic uncertainty and potential adverse harms associated with therapy when managing people, particularly those with cardiometabolic diseases, who have contracted or are at increased risk of contracting COVID‐19. |
Databáze: | OpenAIRE |
Externí odkaz: |